- Home
- APLS
as of 01-16-2026 3:53pm EST
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 2.7B | IPO Year: | 2017 |
| Target Price: | $33.58 | AVG Volume (30 days): | 2.8M |
| Analyst Decision: | Buy | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $16.10 - $31.17 | Next Earning Date: | 02-27-2026 |
| Revenue: | $1,016,397,000 | Revenue Growth: | 42.11% |
| Revenue Growth (this year): | 28.88% | Revenue Growth (next year): | -12.02% |
AI-Powered APLS Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Apellis Pharmaceuticals Inc. (APLS)
Chief Scientific Officer
Avg Cost/Share
$22.19
Shares
2,277
Total Value
$50,520.25
Owned After
1,158,219
SEC Form 4
Chief Technical Officer
Avg Cost/Share
$22.19
Shares
2,618
Total Value
$58,086.09
Owned After
81,046
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$22.19
Shares
3,856
Total Value
$85,553.84
Owned After
107,080
SEC Form 4
General Counsel
Avg Cost/Share
$22.19
Shares
5,780
Total Value
$128,242.02
Owned After
98,838
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$22.19
Shares
10,186
Total Value
$225,998.82
Owned After
321,419
SEC Form 4
VP/Chief Accounting Officer
Avg Cost/Share
$22.19
Shares
873
Total Value
$19,369.43
Owned After
52,595
SEC Form 4
Chief Business & Strat Officer
Avg Cost/Share
$22.19
Shares
1,780
Total Value
$39,493.22
Owned After
83,058
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$25.53
Shares
3,020
Total Value
$77,096.67
Owned After
91,206
SEC Form 4
General Counsel
Avg Cost/Share
$24.49
Shares
5,000
Total Value
$122,450.00
Owned After
98,838
SEC Form 4
General Counsel
Avg Cost/Share
$20.06
Shares
5,000
Total Value
$100,300.00
Owned After
98,838
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Deschatelets Pascal | APLS | Chief Scientific Officer | Jan 13, 2026 | Sell | $22.19 | 2,277 | $50,520.25 | 1,158,219 | |
| Nicholson Nur | APLS | Chief Technical Officer | Jan 13, 2026 | Sell | $22.19 | 2,618 | $58,086.09 | 81,046 | |
| Sullivan Timothy Eugene | APLS | Chief Financial Officer | Jan 13, 2026 | Sell | $22.19 | 3,856 | $85,553.84 | 107,080 | |
| Watson David O. | APLS | General Counsel | Jan 13, 2026 | Sell | $22.19 | 5,780 | $128,242.02 | 98,838 | |
| Francois Cedric | APLS | Chief Executive Officer | Jan 13, 2026 | Sell | $22.19 | 10,186 | $225,998.82 | 321,419 | |
| Chopas James George | APLS | VP/Chief Accounting Officer | Jan 13, 2026 | Sell | $22.19 | 873 | $19,369.43 | 52,595 | |
| DeLong Mark Jeffrey | APLS | Chief Business & Strat Officer | Jan 13, 2026 | Sell | $22.19 | 1,780 | $39,493.22 | 83,058 | |
| Baumal Caroline | APLS | Chief Medical Officer | Jan 5, 2026 | Sell | $25.53 | 3,020 | $77,096.67 | 91,206 | |
| Watson David O. | APLS | General Counsel | Dec 16, 2025 | Sell | $24.49 | 5,000 | $122,450.00 | 98,838 | |
| Watson David O. | APLS | General Counsel | Nov 17, 2025 | Sell | $20.06 | 5,000 | $100,300.00 | 98,838 |
Compare APLS vs Leading Stocks
See how APLS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "APLS Apellis Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.